PNT | tickerfilter.com

Fundamental analysis

26%

Profitability 35%

Dept financing 3%

Liquidity 75%

Performance 10%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

0 0%

1 Year

0 0%

2 Year

81.69%

Key data

Stock price

$12.51

P/E Ratio

0.00

DAY RANGE

N/A - N/A

EPS

$0.00

52 WEEK RANGE

N/A - N/A

52 WEEK CHANGE

N/A

MARKET CAP

904.650 M

YIELD

N/A

SHARES OUTSTANDING

105.683 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

1.26

PUBLIC FLOAT

AVERAGE 10 VOLUME

N/A

AVERAGE 30 VOLUME

N/A

Company detail

CEO: Joe McCann
Region: US
Website: pointbiopharma.com
Employees: 70
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

POINT Biopharma Global Inc. focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioliand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the. treatment of non-metastatic. castration sensitive prostate cancer, which is under study.

PNT - POINT Biopharma Global Inc.